AbbVie stock drops after new schizophrenia drug fails trials

AbbVie Stock Drops After New Schizophrenia Drug Fails Trials

1 week from now

Nov 11, 2024  · The stock had gained 29% this year through Friday’s close, outperforming a 26% rise in the S&P 500. Investors saw AbbVie’s failed trials as good news for Bristol Myers Squibb …

chicagobusiness.com

AbbVie’s Stock Plummets Over 12% After Schizophrenia Drug Flops …

1 week from now

6 days ago  · ABBV. AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to meet its primary …

yahoo.com

AbbVie Tumbles After New Schizophrenia Drug Fails In Two Trials

1 week from now

Nov 11, 2024  · AbbVie Inc. shares sank in early trading after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion …

bloomberg.com

AbbVie Shares Tumble After Schizophrenia Drug Disappoints

1 week from now

Nov 11, 2024  · Shares in AbbVie tumbled after the drugmaker revealed that an experimental treatment for schizophrenia, the main drug purchased as part of an $8.7bn acquisition last …

ft.com

On Wall Street, ‘flat Out’ Failure Of AbbVie Schizophrenia Drug …

1 week from now

Nov 11, 2024  · Through a recent, nearly $9 billion acquisition, AbbVie surged to the front of a new wave of antipsychotic drugs that Wall Street expects to become big sellers.But on Monday, the …

biopharmadive.com

Schizophrenia Drug AbbVie Picked Up In $9 Billion Acquisition Fails …

1 week from now

Nov. 11, 2024. National Biotech Reporter. AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got ...

statnews.com

AbbVie’s $9B Bet Collapses As Closely Watched Schizophrenia Drug …

1 week from now

Nov 11, 2024  · AbbVie lost about $40 billion in market value Monday morning after an experimental drug the company had bet heavily on failed two important clinical trials. The drug, …

yahoo.com

AbbVie Declines After Missing Main Goal In Schizophrenia …

1 week from now

Nov 11, 2024  · AbbVie (NYSE:ABBV) shares dropped about 11% after its mid-stage trials investigating emraclidine as an oral monotherapy treatment for adults with schizophrenia …

seekingalpha.com

Advantage BMS As AbbVie Drug Fails Schizophrenia Trials

1 week from now

Nov 11, 2024  · Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last …

pharmaphorum.com

AbbVie's Closely Watched Schizophrenia Drug Fails Two Studies

1 week from now

By Puyaan Singh and Bhanvi Satija. (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, …

msn.com

Bristol Myers Squibb Stock Rockets — And AbbVie Stock Dives — …

1 week from now

Nov 11, 2024  · Bristol Myers Squibb stock surged 10.5%, ending the regular session at 59.82. Shares have run up markedly since July. After bottoming out at 39.35 on July 5, Bristol Myers …

investors.com

AbbVie's $9B Schizophrenia Prospect Flunks Phase 2 Trials

1 week from now

Nov 11, 2024  · The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to …

fiercebiotech.com

Why This Beaten-Down Dividend Stock Is A No-Brainer Buy On The …

1 week from now

19 hours ago  · Current Price. $164.99. Price as of November 15, 2024, 4:00 p.m. ET. Last year, pharmaceutical giant AbbVie (ABBV -2.73%) lost patent exclusivity for its biggest cash cow, …

fool.com

AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials

1 week from now

Nov 11, 2024  · Company acquired drug as part of $8.7 billion Cerevel purchase; Bristol jumps most in 18 years after competitor’s setback; AbbVie Inc. shares fell the most in more than four …

alphatack.com

Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip …

1 week from now

2 days ago  · AbbVie Inc. (ABBV) is a global biopharmaceutical company, founded in 2013 […] AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final …

yahoo.com

Can This Dividend King Ever Hit $400 After This Major Fail?

1 week from now

1 day ago  · 24/7 Wall St. Insights: AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are now questioning the pharma’s …

247wallst.com